Works matching IS 01676997 AND DT 2016 AND VI 34 AND IP 2

Results: 15

Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 139, doi. 10.1007/s10637-015-0317-4

By:

Silva, Izabella;
Geller, Fabiana;
Persich, Lara;
Dudek, Sabine;
Lang, Karen;
Caro, Miguel;
Durán, Fernando;
Schenkel, Eloir;
Ludwig, Stephan;
Simões, Cláudia

Publication type:

Article

Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 176, doi. 10.1007/s10637-015-0316-5

By:

Kessler, Elizabeth;
Eckhardt, S.;
Pitts, Todd;
Bradshaw-Pierce, Erica;
O'byrant, Cindy;
Messersmith, Wells;
Nallapreddy, Sujatha;
Weekes, Colin;
Spratlin, Jennifer;
Lieu, Christopher;
Kane, Madeleine;
Eppers, Sarah;
Freas, Elizabeth;
Leong, Stephen

Publication type:

Article

Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 149, doi. 10.1007/s10637-015-0318-3

By:

Bao, Xuhui;
Chandramohan, Vidyalakshmi;
Reynolds, Randall;
Norton, John;
Wetsel, William;
Rodriguiz, Ramona;
Aryal, Dipendra;
McLendon, Roger;
Levin, Edward;
Petry, Neil;
Zalutsky, Michael;
Burnett, Bruce;
Kuan, Chien-Tsun;
Pastan, Ira;
Bigner, Darell

Publication type:

Article

Targeting BRAF mutants in clear-cell sarcomas of soft tissue: beyond sarcoma or melanoma classification.

Published in:

2016

By:

Uguen, Arnaud;
Marcorelles, Pascale;
Braekeleer, Marc

Publication type:

Editorial

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 184, doi. 10.1007/s10637-015-0320-9

By:

Cirkel, Geert;
Kerklaan, Bojana;
Vanhoutte, Frédéric;
Aa, Annegret;
Lorenzon, Giocondo;
Namour, Florence;
Pujuguet, Philippe;
Darquenne, Sophie;
Vos, Filip;
Snijders, Tom;
Voest, Emile;
Schellens, Jan;
Lolkema, Martijn

Publication type:

Article

The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 159, doi. 10.1007/s10637-016-0331-1

By:

Kinsella, Paula;
Greene, Lisa;
Bright, Sandra;
Pollock, Jade;
Butini, Stefania;
Campiani, Giuseppe;
Bauer, Sebastian;
Williams, D.;
Zisterer, Daniela

Publication type:

Article

Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 243, doi. 10.1007/s10637-016-0333-z

By:

Gupta, Sumati;
Gouw, Launce;
Wright, Jennifer;
Chawla, Sant;
Pitt, Debbie;
Wade, Mark;
Boucher, Ken;
Sharma, Sunil

Publication type:

Article

Pharmacokinetics, metabolism, and excretion of C-labeled belinostat in patients with recurrent or progressive malignancies.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 193, doi. 10.1007/s10637-015-0321-8

By:

Calvo, Emiliano;
Reddy, Guru;
Boni, Valentina;
García-Cañamaque, Lina;
Song, Tao;
Tjornelund, Jette;
Choi, Mi;
Allen, Lee

Publication type:

Article

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3-1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 202, doi. 10.1007/s10637-016-0325-z

By:

Halstenson, C.;
Shamp, T.;
Gargano, M.;
Walsh, R.;
Patchen, M.

Publication type:

Article

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 216, doi. 10.1007/s10637-016-0327-x

By:

Infante, Jeffrey;
Mendelson, David;
Burris, Howard;
Bendell, Johanna;
Tolcher, Anthony;
Gordon, Michael;
Gillenwater, Heidi;
Arastu-Kapur, Shirin;
Wong, Hansen;
Papadopoulos, Kyriakos

Publication type:

Article

An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 236, doi. 10.1007/s10637-016-0328-9

By:

Necchi, Andrea;
Lo Vullo, Salvatore;
Mariani, Luigi;
Raggi, Daniele;
Giannatempo, Patrizia;
Calareso, Giuseppina;
Togliardi, Elena;
Crippa, Flavio;
Di Genova, Nicola;
Perrone, Federica;
Colecchia, Maurizio;
Paolini, Biagio;
Pelosi, Giuseppe;
Nicolai, Nicola;
Procopio, Giuseppe;
Salvioni, Roberto;
De Braud, Filippo

Publication type:

Article

Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 255, doi. 10.1007/s10637-016-0323-1

By:

Ogasawara, Sadahisa;
Chiba, Tetsuhiro;
Ooka, Yoshihiko;
Suzuki, Eiichiro;
Kanogawa, Naoya;
Saito, Tomoko;
Motoyama, Tenyu;
Tawada, Akinobu;
Kanai, Fumihiko;
Yokosuka, Osamu

Publication type:

Article

A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 231, doi. 10.1007/s10637-016-0324-0

By:

McWhirter, Elaine;
Quirt, Ian;
Gajewski, Thomas;
Pond, Gregory;
Wang, Lisa;
Hui, June;
Oza, Amit

Publication type:

Article

A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 225, doi. 10.1007/s10637-016-0334-y

By:

Kyriakopoulos, Christos;
Heath, Elisabeth;
Eickhoff, Jens;
Kolesar, Jill;
Yayehyirad, Mulusew;
Moll, Thomas;
Wilding, George;
Liu, Glenn

Publication type:

Article

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.

Published in:

Investigational New Drugs, 2016, v. 34, n. 2, p. 168, doi. 10.1007/s10637-015-0314-7

By:

Deming, Dustin;
Cavalcante, Ludmila;
Lubner, Sam;
Mulkerin, Daniel;
LoConte, Noelle;
Eickhoff, Jens;
Kolesar, Jill;
Fioravanti, Suzanne;
Greten, Tim;
Compton, Kathryn;
Doyle, Austin;
Wilding, George;
Duffy, Austin;
Liu, Glenn

Publication type:

Article